



## COVID-19 infection in NMO/SD patients: a French survey

Sinéad Zeidan<sup>1</sup> · Elisabeth Maillart<sup>1</sup> · Céline Louapre<sup>1,2</sup> · Thomas Roux<sup>1</sup> · Catherine Lubetzki<sup>1,2</sup> · Caroline Papeix<sup>1</sup> 

Received: 30 June 2020 / Revised: 21 July 2020 / Accepted: 23 July 2020 / Published online: 12 September 2020  
© Springer-Verlag GmbH Germany, part of Springer Nature 2020

**Keyword** NMO/SD · COVID-19 · Immunosuppressants · AQP4

Dear Sirs,

COVID-19 pandemic due to SARS-CoV2 virus is ongoing, with a fatality rate around 5.4% [1]. Neuromyelitis optica spectrum disorders (NMO/SD) is a rare disabling disease requiring immunosuppressive therapy. The risk of severe COVID-19 remains unknown in NMO/SD. The aim of this case-series study is to describe the prevalence and characteristics of COVID-19 in NMO/SD patients.

We conducted a monocentric retrospective case-series study of NMO/SD patients with highly suspected or proven COVID-19. They fulfilled at least one of the three NMO diagnostic criteria sets [2–4] and were registered in the NOMADMUS cohort (gathering data from French expert NMO/SD centers). Among 117 NMO/SD patients followed in the department of neurology of Pitié Salpêtrière Hospital in Paris, 75 were questioned by phone about COVID-19 infection between 05/05/2020 and 06/15/2020 (33 were lost to follow-up, 9 were unreachable by phone). We collected demographics, neurological history, comorbidities, COVID-19 characteristics and outcome. COVID-19 diagnosis was retained on  $\geq 1$  of the following criteria was fulfilled: (1) positive SARS-CoV2 PCR (naso-pharyngeal swab) or serology (IgG); (2) typical thoracic ground glass opacities on CT scan; (3) acute anosmia/ageusia of sudden onset in the absence of rhinitis or nasal obstruction; (4) typical triad symptoms (cough, fever, asthenia) in epidemic zone of COVID-19. The study received approval from the ethic committee of Sorbonne University (#CER-2020-19).

Demographical and clinical characteristics of the 75 NMO/SD questioned by phone are summarized in Table 1. During the lockdown in France (03/17/2020–05/11/2020), neurologists were available at hospital and by phone/video consults. NMO/SD treatments were maintained, including in-hospital infusions. Patients mostly stopped 100% ( $n = 44$ ; 58.7%) or  $> 50\%$  of their outings ( $n = 29$ ; 38.7%); two patients (2.7%) continued to attend their workplace. Nine patients (12.0%) reported an interaction with a symptomatic person.

Five patients (6.7% of the whole cohort) fulfilled the diagnosis of COVID-19 (Table 2). Their last biological analysis before COVID-19 [median (Q1–Q3) delay: 45 (10–60) days] found: grade 1 lymphopenia ( $n = 3/5$ ) or normal lymphocyte count ( $n = 1/5$ ), and normal neutrophilic counts ( $n = 4/5$ , missing data for one patient). The two patients receiving anti-CD20 treatment had a B-lymphocyte depletion. No patient had a severe infection or neurological state worsening. One patient treated with anti-CD20 and weekly plasmapheresis was hospitalized for closed monitoring he did not require oxygenotherapy, had a normal thoracic CT scan, and plasmapheresis was resumed three weeks later.

In this systematic survey of 75 NMO/SD patients, 6.7% had a highly suspected or confirmed COVID-19, which is consistent with the estimated seroprevalence in Ile-de-France [5]. This rate is slightly higher than the 3.8% prevalence reported in an Iranian study [6], while a large survey in China described a very low risk of COVID-19: 2 confirmed COVID-19 pneumonia out of 3060 NMO/SD patients [7]. Despite ongoing immunosuppressive therapy, no severe infection was encountered in our study. It may be related to the young age and low rate of comorbidity in the infected patients. Some authors reported a favorable outcome of COVID-19 in anti-CD20-treated patients [8,9], possibly due to its minor impact on T-cell counts [10]. A

✉ Caroline Papeix  
caroline.papeix@aphp.fr

<sup>1</sup> Department of Neurology, Pitié Salpêtrière Hospital, APHP, Sorbonne University, 75013 Paris, France

<sup>2</sup> Institut du Cerveau et de la Moelle épinière, ICM, CIC Neuroscience, Paris, France

**Table 1** Characteristics of the NMO/SD cohort (*n* = 75)

Female, <i>n</i> (%)	59 (78.7%)
Age, mean (± SD)	43.9 (± 14.1)
Serology, <i>n</i> (%)	
Positive AQP4-IgG	– 46 (61.3%)
Positive MOG-IgG	– 23 (30.7%)
Negative AQP4- and MOG-IgG	– 6 (8.0%)
EDSS, median [Q1–Q3]	4.5 (2.0–7.0)
Disease duration, median [Q1–Q3]	6.0 (3.0–11.5)
Immunosuppressive treatment, <i>n</i> (%):	
Azathioprine	– 23 (30.7%)
Mycophenolate mofetil	– 19 (25.3%)
Anti-CD20 therapy	– 20 (26.7%)
Plasmapheresis	– 4 (5.3%)
Mitoxantrone	– 1 (1.3%)
Intravenous immunoglobulin	– 1 (1.3%)
Add-on corticotherapy, <i>n</i> (%)	9 (12.0%)

beneficial effect on the inflammatory response to SARS-CoV2 remains to be confirmed [11], but other immunosuppressive treatments are studied for this purpose [12]. As we observed in 2 patients, anti-CD20 treatment may prevent the development of antibodies targeting SARS-CoV2 [8].

Our study has limitations: the sample size is small and COVID-19 tests were poorly available during the outbreak of SARS-CoV2 in France: hence, they were not performed in asymptomatic patients. However, this systematic survey of a French NMO/SD center has resulted in the detection of mild cases of COVID-19 among this immunosuppressed population, which probably would not have been reported otherwise. It highlights a similar prevalence to the local population and a benign course of COVID-19, without any case of flare-up of the neurologic disease. Consistently with a French cohort study on MS patients [13], this survey is reassuring about the risk of severe COVID-19 in NMO/SD-immunosuppressed patients and supports the maintenance of immunosuppressive treatments for NMO/SD during COVID-19 pandemic. Nevertheless, social distancing should still be maintained in case of another outbreak of SARS-CoV2.

**Table 2** Characteristics of NMO/SD patients with confirmed COVID-19 infection, *n* = 5

Patient #	Sex	Age (year)	Comorbidity	Antibody	Antibody status	NMO/SD duration (year)	NMO/SD treatment (duration, year)	Corticotherapy (last 30 days)	EDSS	COVID-19 duration (days)	COVID-19 symptoms	Clinical status (nadir)	COVID-19 test
#1	F	35	None	AQP4-IgG+	AQP4-IgG+	17	Azathioprine (1 y)	No	4	14	Fever, cough, asthenia, headache, diarrhea	No limitation	SARS-CoV2 IgG+
#2	F	27	None	AQP4-IgG+	AQP4-IgG+	6	Azathioprine (2.5y)	No	0	30	Ageusia/anosmia, asthenia, headache	Limitation of activity	Not available
#3	F	27	Obesity	AQP4-IgG+	AQP4-IgG+	11	Mycophenolate mofetil (3y)	No	1	Not available	Ageusia/anosmia, cough, asthenia	No limitation	Not available
#4	M	35	None	AQP4-IgG– and MOG-IgG–	AQP4-IgG– and MOG-IgG–	2	Anti-CD20, Plasmapheresis (1y)	No	6.5	3	Fever	Hospitalized without oxygen	SARS-Cov2 IgG–, PCR+
#5	F	20	None	AQP4-IgG+	AQP4-IgG+	12	Anti-CD20 (2.5y)	No	3	7	Ageusia/anosmia, asthenia	No limitation	SARS-Cov2 IgG–, PCR+

Comorbidity: hypertension, ischemic cardiopathy, obstructive sleep apnea, asthma, pulmonary embolism, diabetes, obesity (BMI > 30 kg/m<sup>2</sup>)  
*F* female, *M* male, *y* years, *d* days

## Compliance with ethical standards

**Conflicts of interest** On behalf of all authors, the corresponding author states that there is no conflict of interest.

## References

1. Tu Y-F, Chien C-S, Yarmishyn AA et al (2020) A Review of SARS-CoV-2 and the ongoing clinical trials. *Int J Mol Sci* 21:2657. <https://doi.org/10.3390/ijms21072657>
2. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic's syndrome). *Neurology* 53:1107–1114. <https://doi.org/10.1212/wnl.53.5.1107>
3. Wingerchuk DM, Lennon VA, Pittock SJ et al (2006) Revised diagnostic criteria for neuromyelitis optica. *Neurology* 66:1485–1489. <https://doi.org/10.1212/01.wnl.0000216139.44259.74>
4. Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology* 85:177–189. <https://doi.org/10.1212/WNL.0000000000001729>
5. Salje H, Tran Kiem C, Lefrancq N et al (2020) Estimating the burden of SARS-CoV-2 in France. *Science*. <https://doi.org/10.1126/science.abc3517>
6. Sahraian MA, Azimi A, Navardi S et al (2020) Evaluation of COVID-19 infection in patients with Neuromyelitis optica spectrum disorder (NMOSD): a report from Iran. *Mult Scler Relat Disord* 44:102245. <https://doi.org/10.1016/j.msard.2020.102245>
7. Fan M, Qiu W, Bu B et al (2020) Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders. *Neurol Neuroimmunol Neuroinflamm*. <https://doi.org/10.1212/NXI.0000000000000787>
8. Meca-Lallana V, Aguirre C, Río B, null et al (2020) COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies. *Mult Scler Relat Disord* 44:102306. <https://doi.org/10.1016/j.msard.2020.102306>
9. Montero-Escribano P, Matías-Guiu J, Gómez-Iglesias P et al (2020) Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain. *Mult Scler Relat Disord* 42:102185. <https://doi.org/10.1016/j.msard.2020.102185>
10. Giovannoni G, Hawkes C, Lechner-Scott J et al (2020) The COVID-19 pandemic and the use of MS disease-modifying therapies. *Mult Scler Relat Disord* 39:102073. <https://doi.org/10.1016/j.msard.2020.102073>
11. Novi G, Mikulska M, Briano F et al (2020) COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? *Mult Scler Relat Disord* 42:102120. <https://doi.org/10.1016/j.msard.2020.102120>
12. Toniati P, Piva S, Cattalini M et al (2020) Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. *Autoimmun Rev* 19:102568. <https://doi.org/10.1016/j.autrev.2020.102568>
13. Louapre C, Collongues N, Stankoff B et al (2020) Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. *JAMA Neurol*. <https://doi.org/10.1001/jamaneurol.2020.2581>